Search

Your search keyword '"Gonzalez-Alvaro, Isidoro"' showing total 129 results
Start Over Author "Gonzalez-Alvaro, Isidoro"
129 results on '"Gonzalez-Alvaro, Isidoro"'

1. Regulation of monocyte apoptosis and DNA extrusion in monocyte extracellular traps by PSGL-1: Relevance in systemic lupus erythematosus

Author

Muñoz-Callejas, Antonio, Sánchez-Abad, Inés, Ramos-Manzano, Alejandra, San Antonio, Esther, González-Sánchez, Elena, Silván, Javier, González-Tajuelo, Rafael, González-Álvaro, Isidoro, García-Pérez, Javier, Tomero, Eva G, García-Vicuña, Rosario, Vicente-Rabaneda, Esther F, Castañeda, Santos, and Urzainqui, Ana

Published
2024
Full Text
View/download PDF

5. COVID-19 severity associates with pulmonary redistribution of [CD1c.sup.+] DCs and inflammatory transitional and nonclassical monocytes

Author

Sanchez-Cerrillo, Ildefonso, Landete, Pedro, Aldave, Beatriz, Sanchez-Alonso, Santiago, Sanchez-Azofra, Ana, Marcos-Jimenez, Ana, Avalos, Elena, Alcaraz-Serna, Ana, de los Santos, Ignacio, Mateu-Albero, Tamara, Esparcia, Laura, Lopez-Sanz, Celia, Martinez-Fleta, Pedro, Gabrie, Ligia, del Campo Guerola, Luciana, de la Fuente, Hortensia, Calzada, Maria J., Gonzalez-Alvaro, Isidoro, Alfranca, Arantzazu, Sanchez-Madrid, Francisco, Munoz-Calleja, Cecilia, Soriano, Joan B., Ancochea, Julio, and Martin-Gayo, Enrique

Subjects
Epidemics -- Control -- Spain, Dendritic cells -- Health aspects, Immune response -- Observations, COVID-19 -- Complications and side effects -- Care and treatment, Health care industry
Abstract

SARS-CoV-2 is responsible for the development of coronavirus disease 2019 (COVID-19) in infected individuals, who can either exhibit mild symptoms or progress toward a life-threatening acute respiratory distress syndrome (ARDS). Exacerbated inflammation and dysregulated immune responses involving T and myeloid cells occur in COVID-19 patients with severe clinical progression. However, the differential contribution of specific subsets of dendritic cells and monocytes to ARDS is still poorly understood. In addition, the role of [CD8.sup.+] T cells present in the lung of COVID-19 patients and relevant for viral control has not been characterized. Here, we have studied the frequencies and activation profiles of dendritic cells and monocytes present in the blood and lung of COVID-19 patients with different clinical severity in comparison with healthy individuals. Furthermore, these subpopulations and their association with antiviral effector [CD8.sup.+] T cell subsets were also characterized in lung infiltrates from critical COVID-19 patients. Our results indicate that inflammatory transitional and nonclassical monocytes and [CD1c.sup.+] conventional dendritic cells preferentially migrate from blood to lungs in patients with severe COVID-19. Thus, this study increases the knowledge of specific myeloid subsets involved in the pathogenesis of COVID-19 disease and could be useful for the design of therapeutic strategies for fighting SARS-CoV-2 infection., Introduction The new SARS-CoV-2 virus causing coronavirus disease 2019 (COVID-19) has unleashed the current pandemic. Individuals infected with this pathogen can either remain asymptomatic or progress from mild to severe [...]

Published
2020
Full Text
View/download PDF

9. REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients

Author

González-Álvaro, Isidoro, Blasco, Antonio J., Lázaro, Pablo, Sánchez-Piedra, Carlos, Almodovar, Raquel, Bachiller-Corral, Javier, Balsa, Alejandro, Caliz, Rafael, Candelas, Gloria, Fernández-Carballido, Cristina, García-Aparicio, Angel, García-Magallón, Blanca, García-Vicuña, Rosario, Gómez-Centeno, Antonio, Ortiz, Ana M., Sanmartí, Raimon, Sanz, Jesús, and Tejera, Beatriz

Published
2017
Full Text
View/download PDF

12. Publisher Correction: A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis

Author

Regueiro, Cristina, Rodriguez-Rodriguez, Luis, Lopez-Mejias, Raquel, Nuño, Laura, Triguero-Martinez, Ana, Perez-Pampin, Eva, Corrales, Alfonso, Villalba, Alejandro, Lopez-Golan, Yolanda, Abasolo, Lydia, Remuzgo-Martínez, Sara, Ortiz, Ana M., Herranz, Eva, Martínez-Feito, Ana, Conde, Carmen, Mera-Varela, Antonio, Balsa, Alejandro, Gonzalez-Alvaro, Isidoro, González-Gay, Miguel Ángel, Fernandez-Gutierrez, Benjamín, and Gonzalez, Antonio

Published
2020
Full Text
View/download PDF

13. A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis

Author

Regueiro, Cristina, Rodriguez-Rodriguez, Luis, Lopez-Mejias, Raquel, Nuño, Laura, Triguero-Martinez, Ana, Perez-Pampin, Eva, Corrales, Alfonso, Villalba, Alejandro, Lopez-Golan, Yolanda, Abasolo, Lydia, Remuzgo-Martínez, Sara, Ortiz, Ana M., Herranz, Eva, Martínez-Feito, Ana, Conde, Carmen, Mera-Varela, Antonio, Balsa, Alejandro, Gonzalez-Alvaro, Isidoro, González-Gay, Miguel Ángel, Fernandez-Gutierrez, Benjamín, and Gonzalez, Antonio

Published
2020
Full Text
View/download PDF

14. Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis

Author

López-Rodríguez, Rosario, Ferreiro-Iglesias, Aida, Lima, Aurea, Bernardes, Miguel, Pawlik, Andrzej, Paradowska‑Gorycka, Agnieszka, Świerkot, Jerzy, Slezak, Ryszard, Gonzalez-Alvaro, Isidoro, Narvaez, Javier, Pérez-Pampín, Eva, Mera-Varela, Antonio, Vidal-Bralo, Laura, Acuña-Ochoa, José Gorgonio, Conde, Carmen, and Gonzalez, Antonio

Published
2018
Full Text
View/download PDF

15. 2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis

Author

Sanmartí, Raimon, García-Rodríguez, Susana, Álvaro-Gracia, José María, Andreu, José Luis, Balsa, Alejandro, Cáliz, Rafael, Fernández-Nebro, Antonio, Ferraz-Amaro, Iván, Gómez-Reino, Juan Jesús, González-Álvaro, Isidoro, Martín-Mola, Emilio, Martínez-Taboada, Víctor Manuel, Ortiz, Ana M., Tornero, Jesús, Marsal, Sara, and Moreno-Muelas, José Vicente

Published
2015
Full Text
View/download PDF

16. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide

Author

Sanmartí, Raimon, García-Rodríguez, Susana, Álvaro-Gracia, José María, Andreu, José Luis, Balsa, Alejandro, Cáliz, Rafael, Fernández-Nebro, Antonio, Ferraz-Amaro, Iván, Gómez-Reino, Juan Jesús, González-Álvaro, Isidoro, Martín-Mola, Emilio, Martínez-Taboada, Víctor Manuel, Ortiz, Ana M., Tornero, Jesús, Marsal, Sara, and Moreno-Muelas, José Vicente

Published
2015
Full Text
View/download PDF

23. Antiviral State of CD1c+ cDC contributes to Increased Maturation and Activation of Cytotoxic Natural Killer cells in Sjogrens Syndrome

Author

Sanchez Cerrillo, Ildefonso, primary, Calvet Mirabent, Marta, additional, Triguero Martinez, Ana, additional, Calzada Fraile, Diego, additional, Delgado Alfaro, Cristina, additional, Valdivia, Mariel, additional, ramirez-Huesca, Marta, additional, Vazquez de Luis, Enrique, additional, Benguria Filippini, Alberto, additional, Moreno Vellisca, Roberto, additional, Adrados, Maria Magdalena, additional, de la Fuente, Hortensia, additional, Tsukalov, Ilya, additional, Roy Vallejo, Emilia, additional, Ramiro, Almudena, additional, Sanchez Madrid, Francisco, additional, Dopazo, Ana, additional, Gonzalez Alvaro, Isidoro, additional, Castaneda Sanz, Santos, additional, and Martin-Gayo, Enrique, additional

Published
2022
Full Text
View/download PDF

24. Consensus Statement of the Spanish Society of Rheumatology on Risk Management of Biologic Therapy in Rheumatic Patients

Author

Gómez Reino, Juan, Loza, Estíbaliz, Andreu, José Luis, Balsa, Alejandro, Batlle, Enrique, Cañete, Juan D., Collantes Estévez, Eduardo, Fernández Carballido, Cristina, Fernández Sueiro, José Luis, García de Vicuña, Rosario, González-Álvaro, Isidoro, González Fernández, Carlos, Juanola, Xavier, Linares, Luis Francisco, Marenco, José Luis, Martín Mola, Emilio, Moreno Ramos, Manuel, Mulero Mendoza, Juan, Muñoz Fernández, Santiago, Queiro, Rubén, Richi Alberti, Patricia, Sanz, Jesús, Tornero Molina, Jesús, Zarco Montejo, Pedro, and Carmona, Loreto

Published
2011
Full Text
View/download PDF

25. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas

Author

Reino, Juan Gómez, Loza, Estíbaliz, Andreu, José Luis, Balsa, Alejandro, Batlle, Enrique, Cañete, Juan D., Collantes Estévez, Eduardo, Fernández Carballido, Cristina, Fernández Sueiro, José Luis, García de Vicuña, Rosario, González-Álvaro, Isidoro, González Fernández, Carlos, Juanola, Xavier, Linares, Luis Francisco, Marenco, José Luis, Martín Mola, Emilio, Moreno Ramos, Manuel, Mulero Mendoza, Juan, Muñoz Fernández, Santiago, Queiro, Rubén, Richi Alberti, Patricia, Sanz, Jesús, Tornero Molina, Jesús, Zarco Montejo, Pedro, and Carmona, Loreto

Published
2011
Full Text
View/download PDF

27. SARS-CoV-2 viremia precedes an IL6 response in severe COVID-19 patients: results of a longitudinal prospective cohort

Author

Roy-Vallejo, Emilia, primary, Cardenoso, Laura, additional, Triguero-Martinez, Ana, additional, Chicot Llano, Marta, additional, Zurita Cruz, Nelly D., additional, Avalos Perez-Urria, Elena, additional, Barrios, Ana, additional, Hernando Santos, Julia, additional, Ortiz, Javier, additional, Rodriguez-Garcia, Sebastian C., additional, Ciudad Sanudo, Marianela, additional, Marcos, Celeste, additional, Garcia Castillo, Elena, additional, Fontan Garcia-Rodrigo, Leticia, additional, Gonzalez, Begona, additional, Mendez, Rosa, additional, Iturrate, Isabel, additional, Sanz-Garcia, Ancor, additional, Villa, Almudena, additional, Sanchez Azofra, Ana, additional, Quicios, Begona, additional, Arribas, David, additional, Alvarez-Rodriguez, Jesus, additional, Patino, Pablo, additional, Trigueros, Marina, additional, Uriarte, Miren, additional, Martin Ramirez, Alexandra, additional, Arevalo, Cristina, additional, Galvan-Roman, Jose Maria, additional, Garcia-Vicuna, Rosario, additional, Ancochea, Julio, additional, Munoz-Calleja, Cecilia, additional, Fernandez-Ruiz, Elena, additional, de la Camara, Rafael, additional, Suarez Fernandez, Carmen, additional, Gonzalez-Alvaro, Isidoro, additional, and Rodriguez Serrano, Diego A., additional

Published
2022
Full Text
View/download PDF

29. Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis

Author

Tornero Molina, Jesús, Sanmartí Sala, Raimon, Rodríguez Valverde, Vicente, Martín Mola, Emilio, Marenco de la Fuente, José Luis, González Álvaro, Isidoro, Muñoz Fernández, Santiago, Gómez-Reino Carnota, Juan, Carreño Pérez, Luis, Batlle Gualda, Enrique, Balsa Criado, Alejandro, Luis Andreu, José, María Álvaro-Gracia, José, Antonio Martínez López, Juan, and Loza Santamaría, Estíbaliz

Published
2010
Full Text
View/download PDF

31. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide

Author

Tornero Molina, Jesús, Sanmartí Sala, Raimon, Rodríguez Valverde, Vicente, Martín Mola, Emilio, Marenco de la Fuente, José Luis, González Álvaro, Isidoro, Muñoz Fernández, Santiago, Gómez-Reino Carnota, Juan, Carreño Pérez, Luis, Batlle Gualda, Enrique, Balsa Criado, Alejandro, Andreu, José Luis, Álvaro-Gracia, José María, Martínez López, Juan Antonio, and Loza Santamaría, Estíbaliz

Published
2010
Full Text
View/download PDF

37. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19 : a meta-analysis

Author

The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, [missing], Domingo, Pere, Mur, Isabel, Mateo, Gracia María, Gutierrez, Maria del Mar, Pomar, Virginia, de Benito, Natividad, Corbacho, Noemí, Herrera, Silvia, Millan, Lucia, Muñoz, Jessica, Malouf, Jorge, Molas, Maria Ema, Asensi, Victor, Horcajada, Juan Pablo, Estrada, Vicente, Gutierrez, Felix, Torres, Ferran, Perez-Molina, Jose A, Fortun, Jesús, Villar, Luisa M, Hohenthal, Ulla, Marttila, Harri, Vuorinen, Tytti, Nordberg, Marika, Valtonen, Mika, Frigault, Matthew J, Mansour, Michael K, Patel, Naomi J, Fernandes, Ana, Harvey, Liam, Foulkes, Andrea S, Healy, Brian C, Shah, Ruta, Bensaci, Ana Maria, Woolley, Ann E., Nikiforow, Sarah, Lin, Nina, Sagar, Manish, Shrager, Harry, Huckins, David S., Axelrod, Matthew, Pincus, Michael D, Fleisher, Jorge, Lampa, Jon, Nowak, Piotr, Vesterbacka, Jan C., Rasmuson, Johan, Skorup, Paul, Janols, Helena, Niward, Katarina F, Chatzidionysiou, Katerina, Asgeirsson, Hilmir, Parke, Åsa, Blennow, Ola, Svensson, Anna-Karin, Aleman, Soo, Sönnerborg, Anders, Henter, Jan-Inge, Horne, Anna Carin, Al-Beidh, Farah, Angus, Derek, Annane, Djillali, Arabi, Yaseen, Beane, Abigail, Berry, Scott, Bhimani, Zahra, Bonten, Marc, Bradbury, Charlotte, Brunkhorst, Frank, Buxton, Meredith, Cheng, Allen, Cove, Matt, De Jong, Menno, Derde, Lennie, Estcourt, Lise, Goossens, Herman, Gordon, Anthony, Green, Cameron, Haniffa, Rashan, Ichihara, Nao, Lamontagne, Francois, Lawler, Patrick, Litton, Ed, Marshall, John, McArthur, Colin, McAuley, Daniel, McGuinness, Shay, McVerry, Bryan, Montgommery, Stephanie, Mouncey, Paul, Murthy, Srinivas, Nichol, Alistair, Parke, Rachael, Parker, Jane, Reyes, Felipe, Rowan, Kathryn, Saito, Hiroki, Santos, Marlene, Seymour, Chris, Shankar-Hari, Manu, Turgeon, Alexis, Turner, Anne, van Bentum-Puijk, Wilma, van de Veerdonk, Frank, Webb, Steve, Zarychanski, Ryan, Baillie, J Kenneth, Beasley, Richard, Cooper, Nichola, Fowler, Robert, Galea, James, Hills, Thomas, King, Andrew, Morpeth, Susan, Netea, Mihai, Ogungbenro, Kayode, Pettila, Ville, Tong, Steve, Uyeki, Tim, Youngstein, Taryn, Higgins, Alisa, Lorenzi, Elizabeth, Berry, Lindsay, Salama, Carlos, Rosas, Ivan O., Ruiz-Antorán, Belén, Muñez Rubio, Elena, Ramos Martínez, Antonio, Campos Esteban, José, Avendaño Solá, Cristina, Pizov, Reuven, Sanz Sanz, Jesus, Abad-Santos, Francisco, Bautista-Hernández, Azucena, García-Fraile, Lucio, Barrios, Ana, Gutiérrez Liarte, Ángela, Alonso Pérez, Tamara, Rodríguez-García, Sebastian C, Mejía-Abril, Gina, Prieto, Jose Carlos, Leon, Rafael, VEIGA, VIVIANE C., SCHEINBERG, PHILLIP, FARIAS, DANIELLE L.C., PRATS, JOÃO G., CAVALCANTI, ALEXANDRE B., MACHADO, FLAVIA R., ROSA, REGIS G., BERWANGER, OTÁVIO, AZEVEDO, LUCIANO C.P., LOPES, RENATO D., DOURADO, LETICIA K., CASTRO, CLAUDIO G., ZAMPIERI, FERNANDO G., AVEZUM, ALVARO, LISBOA, THIAGO C., ROJAS, SALOMÓN S.O., COELHO, JULIANA C., LEITE, RODRIGO T., CARVALHO, JULIO CESAR, ANDRADE, LUIS E.C., SANDES, ALEX R., PINTÃO, MARIA CAROLINA T., SANTOS, SUELI V., ALMEIDA, THIAGO M.L., COSTA, ANDRÉ N., GEBARA, OTAVIO C.E., FREITAS, FLAVIO G.R., PACHECO, EDUARDO S., MACHADO, DAVID J.B., MARTIN, JOSIANE, CONCEIÇÃO, FABIO G., SIQUEIRA, SUELLEN R.R., DAMIANI, LUCAS P., ISHIHARA, LUCIANA M., SCHNEIDER, DANIEL, DE SOUZA, DENISE, Hermine, Olivier, Mariette, Xavier, Tharaux, Pierre Louis, Resche Rigon, Matthieu, Porcher, Raphael, Ravaud, Philippe, Azoulay, Elie, Cadranel, Jacques, Emmerich, Joseph, Fartoukh, Muriel, Guidet, Bertrand, Humbert, Marc, Lacombe, Karine, Mahevas, Matthieu, Pene, Frédéric, Pourchet-Martinez, Valérie, Schlemmer, Frédéric, Tibi, Annick, Yazdanpanah, Yazdan, Dougados, Maxime, Bureau, Serge, Horby, Peter W, Landray, Martin J, Baillie, Kenneth J, Buch, Maya H, Chappell, Lucy C, Day, Jeremy N, Faust, Saul N, Haynes, Richard, Jaki, Thomas, Jeffery, Katie, Juszczak, Edmund, Lim, Wei Shen, Mafham, Marion, Montgomery, Alan, Mumford, Andrew, Thwaites, Guy, Kamarulzaman, Adeeba, Syed Omar, Sharifah Faridah, Ponnampalavanar, Sasheela, Raja Azwa, Raja Iskandar Syah, Wong, Pui Li, Kukreja, Anjanna, Ong, Hang Cheng, Sulaiman, Helmi, Basri, Sazali, Ng, Rong Xiang, Megat Johari, Bushra, Rajasuriar, Reena, Chong, Meng Li, Neelamegam, Malinee, Syed Mansor, Syed Mukhtar, Zulhaimi, Nurul Syuhada, Lee, Cheng Siang, Altice, Frederick, Price, Christina, Malinis, Maricar, Hasan, Mohd Shahnaz, Wong, Chee Kuan, Chidambaram, Suresh, Misnan, Nor Arisah, Mohd Thabit, Alif Adlan, Sim, Benedict, Bidin, Farah Nadiah, Mohd Abd Rahim, Mohd Abd Hafiz, Saravanamuttu, Sujana, Tuang, Wei Xuan, Mohamed Gani, Yasmin, Thangavelu, Suvintheran, Tay, Kim Heng, Ibrahim, Nur Munirah, Halid, Luqman Alhakim, Tan, Kok Tong, Mukri, Mohd Noor Azreet, Arip, Masita, Koh, Hui Moon, Syed Badaruddin, Syarifah Nurul Ain, Raja Sureja, Letchumi, Chun, Geok Ying, TORRE-CISNEROS, JULIAN, MERCHANTE, NICOLAS, LEON, RAFAEL, CARCEL, SHEILA, GARRIDO, JOSE CARLOS, Galun, Eitan, Soriano, Alex, Martínez, José Antonio, Castán, Clara, Paredes, Roger, Dalmau, David, Carbonell, Cristina, Espinosa, Gerard, Castro, Pedro, Muñóz, José, Almuedo, Alex, Prieto, Sergio, Pacheco, Iván, Ratain, Mark, Pisano, Jennifer, Strek, Mary, Adegunsoye, Ayodeji, Karrison, Theodore, Declercq, Jozefien, Van Damme, Karel, De Leeuw, Elisabeth, Bosteels, Cedric, Maes, Bastiaan, Vale, Claire L., Godolphin, Peter J., Fisher, David, Higgins, Julian P. T., Spiga, Francesca, Savovic, Jelena, Tierney, Jayne, Baron, Gabriel, Benbenishty, Julie S., Berry, Lindsay R., Broman, Niklas, Cavalcanti, Alexandre Biasi, Colman, Roos, De Buyser, Stefanie, Derde, Lennie P. G., Omar, Sharifah Faridah, Fernandez-Cruz, Ana, Feuth, Thijs, Garcia, Felipe, Garcia-Vicuna, Rosario, Gonzalez-Alvaro, Isidoro, Gordon, Anthony C., Horby, Peter W., Horick, Nora K., Kumar, Kuldeep, Lambrecht, Bart, Landray, Martin J., Leal, Lorna, Lederer, David J., Merchante, Nicolas, Mohan, Shalini V., Nivens, Michael C., Oksi, Jarmo, Perez-Molina, Jose A., Postma, Simone, Ramanan, Athimalaipet V., Reid, Pankti D., Rutgers, Abraham, Sancho-Lopez, Aranzazu, Seto, Todd B., Sivapalasingam, Sumathi, Soin, Arvinder Singh, Staplin, Natalie, Stone, John H., Strohbehn, Garth W., Sunden-Cullberg, Jonas, Torre-Cisneros, Julian, Tsai, Larry W., van Hoogstraten, Hubert, van Meerten, Tom, Veiga, Viviane Cordeiro, Westerweel, Peter E., Diaz, Janet V., Marshall, John C., Sterne, Jonathan A. C., Translational Immunology Groningen (TRIGR), Stem Cell Aging Leukemia and Lymphoma (SALL), World Health Organization, and Group, WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working

Subjects
Male, medicine.medical_specialty, Randomization, Secondary infection, Placebo, Antibodies, Monoclonal, Humanized, Internal medicine, Cause of Death, Medicine and Health Sciences, Medicine, Humans, Prospective Studies, Prospective cohort study, Glucocorticoids, METAANALYSIS, Cause of death, Aged, Randomized Controlled Trials as Topic, business.industry, Coinfection, Interleukin-6, COVID-19, Odds ratio, General Medicine, Middle Aged, Respiration, Artificial, COVID-19 Drug Treatment, Clinical trial, Hospitalization, Meta-analysis, Disease Progression, Drug Therapy, Combination, Female, business
Abstract

[Importance] Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm., [Objective] To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes., [Data Sources] Trials were identified through systematic searches of electronic databases between October 2020 and January 2021. Searches were not restricted by trial status or language. Additional trials were identified through contact with experts., [Study Selection] Eligible trials randomly assigned patients hospitalized for COVID-19 to a group in whom IL-6 antagonists were administered and to a group in whom neither IL-6 antagonists nor any other immunomodulators except corticosteroids were administered. Among 72 potentially eligible trials, 27 (37.5%) met study selection criteria., [Data Extraction and Synthesis] In this prospective meta-analysis, risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I2 statistic. The primary analysis was an inverse variance–weighted fixed-effects meta-analysis of odds ratios (ORs) for 28-day all-cause mortality., [Main Outcomes and Measures] The primary outcome measure was all-cause mortality at 28 days after randomization. There were 9 secondary outcomes including progression to invasive mechanical ventilation or death and risk of secondary infection by 28 days., [Results] A total of 10 930 patients (median age, 61 years [range of medians, 52-68 years]; 3560 [33%] were women) participating in 27 trials were included. By 28 days, there were 1407 deaths among 6449 patients randomized to IL-6 antagonists and 1158 deaths among 4481 patients randomized to usual care or placebo (summary OR, 0.86 [95% CI, 0.79-0.95]; P = .003 based on a fixed-effects meta-analysis). This corresponds to an absolute mortality risk of 22% for IL-6 antagonists compared with an assumed mortality risk of 25% for usual care or placebo. The corresponding summary ORs were 0.83 (95% CI, 0.74-0.92; P, [Conclusions and Relevance] In this prospective meta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality., [Trial Registration] PROSPERO Identifier: CRD42021230155., Funding for administrative and communications support was provided by the World Health Organization.

Published
2021

38. Evaluation of two RT-PCR techniques for SARS-CoV-2 RNA detection in serum for microbiological diagnosis

Author

Martin Ramirez, Alexandra, primary, Zurita Cruz, Nelly Daniella, additional, Gutierrez-Cobos, Ainhoa, additional, Rodriguez Serrano, Diego Anibal, additional, Gonzalez Alvaro, Isidoro, additional, Roy Vallejo, Emilia, additional, Gomez de Frutos, Sara, additional, Fontan Garcia-Rodrigo, Leticia, additional, and Cardenoso Domingo, Laura, additional

Published
2020
Full Text
View/download PDF

40. The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity

Author

Gonzalez-Alvaro, Isidoro, Castrejon, Isabel, Carmona, Loreto, Dougados, M., Huizinga, T., Abu Shakra, M., Alberts, A., Alperi Lopez, M., Amital, H., Aringer, M., Aslanidis, S., Berenbaum, F., Bijlsma, H., Blanco Garcia, F. J., Bliddal, H., Borofsky, M., Brocq, O., Buldakov, S., Cantini, F., Carreno Perez, L., Chahade, W., Ciconelli, R., Codreanu, C., Dahlqvist, S. R., Damjanov, N., Diamantopoulos, A., Dimdina, L., Dimic, A., Dorokhov, A., Dubikov, A., Fadienko, G., Fano, N., Ferreira, G., Gabrielli, A., Gaffney, K., Gaudin, P., Gerlag, D. M., Gerli, R., Goncalves, C. R., Hansen, M. S., Hanvivadhanakul, P., Hoili, C., Hou, A., Hunter, J., Ilic, T., Ionescu, R., Kaine, J., Kakurina, N., Kamalova, R., Kelly, T., Knyazeva, L., Krumina, L., Kurthen, R., Lagrone, R. P., Lapadula, G., Lavrentjevs, V, Lawson, J. G., Lazic, Z., Lejnieks, A., Levy, Y., Lexberg, A., Mader, R., Mariette, X., Markovits, D., Mola, Martin E., Maugars, Y., Guarch, Maymo J., Mazurov, V., I, Mikkelsen, K., Vergles, Morovic J., Nabizadeh, S., Nanagara, R., Nasonov, E. L., Sarabia, Navarro F., Neumann, T., Novak, S., Olech, E., Oza, M., Paran, D., Parsik, E., Pegram, S., Suarez, Pombo M., Popova, T., Puechal, X., Raja, N., Ridley, D., Rosner, I, Rubbert-Roth, A., Rudin, A., Saraux, A., Saulite-Kandevica, D., Settas, L., Sfikakis, P., Sheeran, T., Sizikov, A., Stamenkovic, D., Stefanovic, D., Stolow, J. B., Tan, A. L., Tebib, J., Tishler, M., Tony, H. P., Troum, O. M., Uaratanawong, S., Ucar Angulo, E., Valenzuela, G., van der Laken, K., Van Laar, J., van Riel, P. L. C. M., Vasilopoulos, D., Veldi, T., Vinogradova, I, Vosse, D., Wassenberg, S., Weidmann, C., Weitz, M., Wollenhaupt, J., Xavier, R., Yakupova, S., Zagar, I, Zavgorodnaja, T., Zemerova, E., Zisman, D., Zonova, E., Camona, Loreto, Abasolo Alcazar, L., Alegre de Miguel, C., Andreu Sanchez, J. L., Aragon Diez, A., Balsa Criado, A., Batlle Gualda, E., Belmonte Serrano, M. A., Beltran Audera, J., Beltran Fabregat, J., Bonilla Hernan, G., Caro Fernandez, N., Casado, E., Cebrian Mendez, L., Corteguera Coro, M., Cuadra Diaz, J. L., Cuesta, E., Fiter Areste, J., Freire Gonzalez, M., Galindo Izquierdo, M., Garcia Meijide, J. A., Garcia Gomez, M. C., Gimenez Ubeda, E., Gomez Centeno, E., Gomez Vaquero, C., Gonzalez Fernandez, M. J., Gonzalez Gomez, M. L., Gonzalez Hernandez, T., Gonzalez-Alvaro, I, Gonzalez-Montagut Gomez, C., Grandal Delgado, Y., Gratacos Masmitja, J., Hernandez del Rio, A., Instxaurbe, A. R., Irigoyen Oyarzabal, M., V, Jimenez Palop, M., Juan Mas, A., Judez Navarro, E., Larrosa Padro, M., Lopez Longo, F. J., Loza Santamaria, E., Maese Manzano, J., Manero Ruiz, F. J., Mateo Bernardo, I, Mayordomo Gonzalez, L., Mazzucheli, R., Medrano San Idelfonso, M., Naranjo Hernandez, A., Pecondon Espanol, A., Peiro Callizo, E., Quiros Donate, J., Ramos Lopez, P., Rivera Redondo, J., Rodriguez Gomez, M., Rodriguez Lopez, M., Rosello Pardo, R., Sampedro Alvarez, J., Sanmarti Sala, R., Rey Rey, Santos J., Tena Marsa, X., Tenorio Martin, M., Torres Martin, M. C., Urena Garnica, I, Valdazo de Diego, J. P., Valls, M., Villaverde Garcia, V., Zarco Montejo, P., Zubieta Tabernero, J., Balsa, Alejandro, Sanmarti, Raimon, Cabezas, J. A., Cantalejo, M., Chamizo, E., Ciruelo, E., Corrales, A., Cruz, A., Diaz, C., Fiter, J., Freire, M. M., Galindo, M., Garcia de Vicuna, M. R., Gelman, S. M., Gonzalez Crespo, R., Gonzalez Fernandez, C., Gracia, A., Granados, J., Guzman, M. A., Irigoyen, M., V, Juan, A., Juanola, X., Laiz, A., Manero, F. J., Martinez, A., Martinez, F., Mata, C., Maymo, J., Navarro, F. J., Peiro, E., Perez, F., Perez, G., Perez, M., Pujol, M., Quiros, J., Ribas, B., Riera, M., Rivera, J., Rodriguez, J. M., Rosello, R., Tenorio, M., Toyos, F. J., ACT-RAY Study Grp, PROAR Study Grp, EMECAR Study Grp, Interne Geneeskunde, MUMC+: MA Reumatologie (9), and RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation

Subjects
Male, medicine.medical_specialty, Science, humanos, Severity of Illness Index, RECOMMENDATIONS, VALIDATION, VARIABLES, ensayos clínicos como asunto, Arthritis, Rheumatoid, Cohort Studies, Internal medicine, Linear regression, Severity of illness, medicine, Humans, índice de gravedad de la enfermedad, estudios de cohortes, mediana edad, Clinical Trials as Topic, DISEASE-ACTIVITY MEASURES, Multidisciplinary, SCORES, business.industry, Arthritis, resultado del tratamiento, modelos lineales, Secondary data, Gold standard (test), Middle Aged, medicine.disease, Clinical trial, Treatment Outcome, Rheumatoid arthritis, Antirheumatic Agents, Cohort, Linear Models, Medicine, Female, GENDER, business, antirreumáticos, artritis, Cohort study
Abstract

Objective To evaluate the responsiveness in terms of correlation of the Hospital Universitario La Princesa Index (HUPI) comparatively to the traditional composite indices used to assess disease activity in rheumatoid arthritis (RA), and to compare the performance of HUPI-based response criteria with that of the EULAR response criteria. Methods Secondary data analysis from the following studies: ACT-RAY (clinical trial), PROAR (early RA cohort) and EMECAR (pre-biologic era long term RA cohort). Responsiveness was evaluated by: 1) comparing change from baseline (Delta) of HUPI with Delta in other scores by calculating correlation coefficients; 2) calculating standardised effect sizes. The accuracy of response by HUPI and by EULAR criteria was analyzed using linear regressions in which the dependent variable was change in global assessment by physician (Delta GDA-Phy). Results Delta HUPI correlation with change in all other indices ranged from 0.387 to 0.791); HUPI's standardized effect size was larger than those from the other indices in each database used. In ACT-RAY, depending on visit, between 65 and 80% of patients were equally classified by HUPI and EULAR response criteria. However, HUPI criteria were slightly more stringent, with higher percentage of patients classified as non-responder, especially at early visits. HUPI response criteria showed a slightly higher accuracy than EULAR response criteria when using Delta GDA-Phy as gold standard. Conclusion HUPI shows good responsiveness in terms of correlation in each studied scenario (clinical trial, early RA cohort, and established RA cohort). Response criteria by HUPI seem more stringent than EULAR's., Our study was supported by grants RD16/0012/0011 and PI14/00442 from the Ministerio de Economia y Competitividad (Instituto de Salud Carlos III; Spain) and cofunded by the Fondo Europeo de Desarrollo Regional (FEDER). Data from ACT-RAY clinical trial were kindly provided by Hoffmann-La Roche Ltd. No financial support was received from Hoffmann-La Roche Ltd Data from EMECAR and PROAR cohorts were provided by the Spanish Society of Rheumatology. No financial support was received from the Spanish Society of Rheumatology. None of these institutions played any role in the analysis or interpretation of data, nor were they involved in the writing of the manuscript. Roche and Sociedad Espanola de Reumatologia were involved in the collection of data from ACT-RAY, and EMECAR and PROAR, respectively. However, these funders had no role in study design, analysis, decision to publish, or preparation of the manuscript.

Published
2019

41. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists

Author

Gonzalez-Alvaro, Isidoro, Ortiz, Ana M, Tomero, Eva G, Balsa, Alejandro, Orte, Javier, Laffon, Armando, and Garcia-Vicuna, Rosario

Subjects
Rheumatoid arthritis -- Complications and side effects, Rheumatoid arthritis -- Development and progression, Tumor necrosis factor -- Physiological aspects, Antirheumatic agents -- Dosage and administration, Antirheumatic agents -- Complications and side effects, Health
Published
2007

42. HLA–B*08 Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti–Carbamylated Protein Antibody–Positive/Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis.

Author

Regueiro, Cristina, Casares‐Marfil, Desire, Lundberg, Karin, Knevel, Rachel, Acosta‐Herrera, Marialbert, Rodriguez‐Rodriguez, Luis, Lopez‐Mejias, Raquel, Perez‐Pampin, Eva, Triguero‐Martinez, Ana, Nuño, Laura, Ferraz‐Amaro, Ivan, Rodriguez‐Carrio, Javier, Lopez‐Pedrera, Rosario, Robustillo‐Villarino, Montse, Castañeda, Santos, Remuzgo‐Martinez, Sara, Alperi, Mercedes, Alegre‐Sancho, Juan J., Balsa, Alejandro, and Gonzalez‐Alvaro, Isidoro

Subjects
RHEUMATOID arthritis risk factors, AUTOANTIBODIES, ALLELES, RISK assessment, DISEASE susceptibility, GENOMES, LOGISTIC regression analysis, AMINO acids
Abstract

Objective: Previously, only the HLA–DRB1 alleles have been assessed in rheumatoid arthritis (RA). The aim of the present study was to identify the key major histocompatibility complex (MHC) susceptibility factors showing a significant association with anti–carbamylated protein antibody–positive (anti‐CarP+) RA. Methods: Analyses were restricted to RA patients who were anti–cyclic citrullinated peptide antibody negative (anti‐CCP−), because the anti‐CCP status dominated the results otherwise. Therefore, we studied samples from 1,821 anti‐CCP− RA patients and 6,821 population controls from Spain, Sweden, and the Netherlands. The genotypes for ~8,000 MHC biallelic variants were assessed by dense genotyping and imputation. Their association with the anti‐CarP status in RA patients was tested with logistic regression and combined with inverse‐variance meta‐analysis. Significance of the associations was assessed according to a study‐specific threshold of P < 2.0 × 10−5. Results: The HLA–B*08 allele and its correlated amino acid variant Asp‐9 showed a significant association with anti‐CarP+/anti‐CCP− RA (P < 3.78 × 10−7; I2 = 0). This association was specific when assessed relative to 3 comparator groups: population controls, anti‐CarP−/anti‐CCP− RA patients, and anti‐CCP− RA patients who were positive for other anti–citrullinated protein antibodies. Based on these findings, anti‐CarP+/anti‐CCP− RA patients could be separated from other antibody‐defined subsets of RA patients in whom an association with the HLA–B*08 allele has been previously demonstrated. No other MHC variant remained associated with anti‐CarP+/anti‐CCP− RA after accounting for the presence of the HLA–B*08 allele. Specifically, the reported association of HLA–DRB1*03 was observed at a level comparable to that reported previously, but it was attributable to linkage disequilibrium. Conclusion: These results identify HLA–B*08 carrying Asp‐9 as the MHC locus showing the strongest association with anti‐CarP+/anti‐CCP− RA. This knowledge may help clarify the role of the HLA in susceptibility to specific subsets of RA, by shaping the spectrum of RA autoantibodies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results